Corvus Pharma Insider Update: OrbiMed Cashless Warrant Exercise & Share Sale
Rhea-AI Filing Summary
Form 4 filing for Corvus Pharmaceuticals (CRVS) dated 07/01/2025 details insider transactions by OrbiMed-affiliated entities.
- Warrant exercise: On 06/27/2025, OrbiMed Private Investments V, LP ("OPI V") exercised 1,397,684 common stock warrants at $3.50 per share.
- Cashless settlement: The transaction was executed on a cashless basis. To satisfy the $4.9 million aggregate exercise price, the issuer withheld 1,176,332 warrant shares, issuing the remaining 221,352 shares to OPI V.
- Open-market disposition: Table I also shows a Code "S" disposal of the same 1,176,332 shares at an average price of $4.1586.
- Post-transaction holdings: OrbiMed’s indirect beneficial ownership declined from 8,341,338 to 7,165,006 common shares, but it remains a >10% shareholder and board-represented director.
- Control structure: OPI V is controlled by OrbiMed Capital GP V LLC (general partner) and OrbiMed Advisors LLC (managing member). Each entity disclaims beneficial ownership except to the extent of pecuniary interest.
The filing signals routine warrant housekeeping before the 06/30/2025 expiry rather than a strategic shift. The cashless feature limits share issuance to 221,352 new shares, a modest dilution relative to OrbiMed’s prior stake. Nonetheless, the simultaneous disposition reduces OrbiMed’s ownership by roughly 14%, which investors may view as a slight negative sentiment indicator.
Positive
- Limited dilution: Only 221,352 new shares were issued despite 1.40 m warrants exercised, minimizing impact on total share count.
- Continued >10% ownership: OrbiMed retains 7.17 m shares and a board seat, indicating ongoing strategic interest.
Negative
- 14% reduction in holdings: Disposal of 1.18 m shares lowers OrbiMed’s stake from 8.34 m to 7.17 m shares, potentially signaling reduced confidence.
- Potential selling pressure: The sale at $4.1586 could weigh on short-term share performance if interpreted as insider selling.
Insights
TL;DR—OrbiMed exercised expiring warrants cashlessly, added 221k shares but sold 1.18 m, trimming stake to 7.17 m shares.
The key takeaway is position management rather than directional conviction. Exercising before the 06/30/2025 expiry avoided warrant lapse while the cashless structure conserved cash. Net dilution is limited (≈221k shares). However, disposing of 1.18 m shares—14% of the prior position—reduces alignment with minority shareholders and could create modest selling pressure near the $4.16 execution price. Given Corvus’s small-cap profile, the trade is noteworthy but not transformational.
TL;DR—Stakeholder still >10% owner with board seat; governance influence unchanged.
OrbiMed, through OPI V, maintains director representation (Peter A. Thompson) and remains above the 10% ownership threshold, preserving Section 16 filing obligations and significant governance leverage. The disclaimer language reiterates limited beneficial ownership claims, standard for investment advisers. From a governance standpoint, continuity of influence outweighs the moderate share reduction, suggesting neutral overall impact.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| X | Common Warrants (right to buy) | 1,397,684 | $0.00 | -- |
| X | Common Stock | 1,397,684 | $3.50 | $4.89M |
| Sale | Common Stock | 1,176,332 | $4.1586 | $4.89M |
Footnotes (1)
- On June 27, 2025, OrbiMed Private Investments V, LP ("OPI V") exercised common warrants ("Warrants") to purchase 1,397,684 shares of the Issuer's Common Stock for $3.50 per share. OPI V paid the exercise price on a cashless basis, resulting in the Issuer withholding 1,176,332 of the Warrant shares to pay the exercise price and issuing to OPI V the remaining 221,352 shares. These securities are held of record by OPI V. OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V. This report on Form 4 is jointly filed by OrbiMed Advisors and GP V. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP V have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
